 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of GrowthALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE...

Axogen Announces Transition of Finance Team Leadership

Key Insights Given the large stake in the stock by institutions, AxoGen's stock price might be vulnerable to their...

Great week for AxoGen, Inc. (NASDAQ:AXGN) institutional investors after losing 41% over the previous year

ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries...

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AxoGen (NASDAQ:AXGN  Get Free Report) was downgraded by stock analysts at StockNews.com from a buy rating to a hold rating in a report released on Tuesday. Several...

StockNews.com Downgrades AxoGen (NASDAQ:AXGN) to Hold

Investors eyeing a purchase of Axogen Inc (AXGN) shares, but cautious about paying the going market price of 5.95/share, might benefit from considering selling puts among the alternative...

Commit To Purchase Axogen At $5, Earn 14.7% Annualized Using Options

AXGN's total volume now sits at 1.5M. The +-1.16% price change was insignificant, leaving IBM's price at $5.98...

The volume for Axogen stock increased for one day, resulting in a record-breaking daily growth of 257% of the 65-Day Volume Moving Average

ALACHUA and TAMPA, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries...

Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference

AxoGen (NASDAQ:AXGN  Get Free Report) was upgraded by investment analysts at StockNews.com from a hold rating to a buy rating in a research note issued to investors...

AxoGen (NASDAQ:AXGN) Rating Increased to Buy at StockNews.com

Shares of AxoGen, Inc. (NASDAQ:AXGN  Get Free Report) have earned a consensus recommendation of Buy from the four research firms that are currently covering the firm...

Analysts Set AxoGen, Inc. (NASDAQ:AXGN) Price Target at $15.00

This is a signal that AXGN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Axogen (AXGN, $5.62) RSI Indicator left the overbought zone on November 14, 2023

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Watchers	1,184
52-Wk Low	$3.45
52-Wk High	$11.32

Market Cap	$296.14M
Volume (M)	490,796.00
52-Wk High	$11.32
52-Wk Low	$3.45

AXGN Axogen Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals